Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade B 165.54 1.96% 3.18
BGNE closed up 1.96 percent on Friday, May 29, 2020, on 1.66 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BGNE trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
NR7 Range Contraction 1.96%
MACD Bearish Signal Line Cross Bearish 2.87%
20 DMA Support Bullish 2.87%
Multiple of Ten Bullish Other 2.87%
180 Bullish Setup Bullish Swing Setup 1.00%
Multiple of Ten Bullish Other 1.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.03%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 210.35
52 Week Low 113.01
Average Volume 315,662
200-Day Moving Average 155.85
50-Day Moving Average 150.22
20-Day Moving Average 158.23
10-Day Moving Average 164.36
Average True Range 6.80
ADX 20.83
+DI 24.91
-DI 17.61
Chandelier Exit (Long, 3 ATRs ) 151.00
Chandelier Exit (Short, 3 ATRs ) 156.88
Upper Bollinger Band 176.63
Lower Bollinger Band 139.83
Percent B (%b) 0.7
BandWidth 23.26
MACD Line 3.20
MACD Signal Line 3.36
MACD Histogram -0.1588
Fundamentals Value
Market Cap 6.59 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -33.31
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 179.00
Resistance 3 (R3) 178.18 172.88 176.75
Resistance 2 (R2) 172.88 169.45 173.29 176.00
Resistance 1 (R1) 169.21 167.34 171.05 170.03 175.26
Pivot Point 163.91 163.91 164.83 164.32 163.91
Support 1 (S1) 160.24 160.48 162.08 161.06 155.82
Support 2 (S2) 154.94 158.37 155.35 155.08
Support 3 (S3) 151.27 154.94 154.33
Support 4 (S4) 152.09